RE: late TR1 from beginning of Aug... bet they've bought more since...30 Aug 2022 12:35
Orphin pharma - website states
‘We are in the business of aquisitions of intellectial properties in the medical area”
Not buying for the sake of a jolly.
This is happening:))P
About AOP Orphan Pharmaceuticals AG
AOP Orphan is a multinational company with headquarters in Vienna, Austria focusing on clinical development, marketing and distribution of medicines for rare and complex diseases. AOP Orphan provides innovative treatment options, further individualized and customized services to meet physicians and patients needs across Europe, the Middle East & Asia. Currently, AOP Orphan is specializing in therapeutic solutions for HematoOncology, Cardiology & Pulmonology and Neurology & Metabolic Disorders.
To stay updated, follow AOP Orphan on LinkedIn: https://www.linkedin.com/company/aop-orphan-pharmaceuticals/
About AOP Orphan IP AG
AOP Orphan IP AG is a member of the group of companies of AOP Orphan International AG with headquarters in Vaduz, Principality of Liechtenstein, the core activity of which is the acquisition, development and commercial exploitation of intellectual properties, mainly in the medical area. An increasingly growing importance lies in the research and development of medical and related technical products.
About orphanix GmbH
orphanix GmbH is a medical development company headquartered in Linz / Austria. In line with its mission of “Filling the blind spot in medicine”, orphanix is dedicated to developing innovative solutions for high unmet medical needs in the rare disease space. orphanix has received orphan designations for prevention of neonatal diseases by EMA and FDA.
Sign In
Follow the stocks
